drugset / Trial / NCT05480293
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.
Timeline
- Start
- 2023-02-14
- Primary completion
- 2025-07-31
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | SCT510A | Monoclonal antibody | 1.25 mg | Intravitreal |